Johns Hopkins Medicine researchers have achieved a remarkable breakthrough in the field of immunotherapy by engineering biodegradable nanoparticles that can reprogram immune cells inside the body to combat diseases such as blood cancers and autoimmune disorders effectively. This simplified nanoparticle design offers a revolutionary alternative to traditional chimeric antigen receptor T cell (CAR-T) therapies, which currently involve laborious and costly processes of isolating, modifying, and expanding immune cells outside the patient’s body. Instead, these cutting-edge nanoparticles can be administered directly, prompting the immune system to self-engineer and launch targeted attacks against harmful cells.
Traditional CAR-T treatments, while successful in some blood cancer cases, have faced limitations due to their complexity, expense, and time-consuming nature. The Johns Hopkins team’s innovative approach circumvents this by delivering a nanotechnological payload that automatically activates and modifies T cells—the warriors of the immune system—in vivo. This breakthrough has the potential to democratize access to life-saving immunotherapies and dramatically streamline treatment protocols, reducing barriers posed by existing methodologies.
The core of these nanoparticles is formed from biodegradable polymers composed of ester units, which safely degrade within aqueous environments such as the bloodstream. The surface of each nanoparticle is meticulously functionalized with two antibodies: antiCD3 and antiCD28. These critical molecules serve as homing devices, enabling the nanoparticles to precisely locate and bind to T cells scattered throughout the blood and lymphoid tissues. Upon engagement, the nanoparticles not only stimulate T cell activation but also facilitate internalization, which is pivotal for subsequent genetic reprogramming.
Encased within the molecular shell of these “ship-like” nanoparticles lies messenger RNA (mRNA) – a transient genetic blueprint that instructs T cells to express receptors specifically designed to detect and eliminate B cells that contribute to diseases like lupus, leukemia, and lymphoma. By delivering mRNA payloads directly inside T cells, the nanoparticles roundly bypass the challenges of cellular engineering outside the body, enabling an internal transformation of immune cells into potent, disease-targeting agents.
In rigorous preclinical trials involving healthy murine models, a single injection of these nanoparticles resulted in a staggering 95% reduction of circulating B cells within just 24 hours. Furthermore, approximately half of the B cells residing in the spleen were depleted, showcasing the nanoparticles’ systemic reach and effective targeting capabilities. Remarkably, even after a week, blood B cells remained suppressed at about 50% of their original levels, illustrating a potent yet controlled immune modulation.
The stepwise operational mechanism of these nanoparticles is as ingenious as it is elegant. Comparable to multi-stage rockets designed for outer space missions, these engineered carriers embark on an “inner space” voyage, first engaging and activating target T cells, then penetrating cellular membranes, and finally degrading to unleash mRNA cargoes. This programmed release not only ensures successful mRNA transfer but also prevents unintended degradation, an obstacle that commonly hinders intracellular delivery vehicles.
Delivering genetic material specifically to T cells presents unique challenges, as these cells possess intrinsic defenses to resist uptake and neutralize foreign particles—a feature evolved to prevent viral hijacking such as seen in HIV infections. The Johns Hopkins team overcame this biological defense by optimizing nanoparticle composition and surface chemistry, achieving approximately a 10% success rate of mRNA escape from intracellular degradation compartments inside T cells, which is substantially higher than the 1% to 2% efficiency observed with many other nanoparticle platforms.
The engineered nanoparticles were benchmarked against commercially available magnetic beads traditionally used for T cell stimulation in laboratory settings. Results demonstrated equivalent efficacy in T cell activation levels, but with the significant advantage that the nanoparticles advanced one step further by penetrating the cells to initiate genetic reprogramming. This dual functionality underscores the therapeutic promise of the technology, enabling both priming and modification of immune cells in a seamless process.
This pioneering research signifies a convergence of immunology and biomedical engineering disciplines at Johns Hopkins. By fusing knowledge from artificial immune cell development and polymer-based nanocarriers, the team has fashioned a streamlined immunotherapeutic tool with scalable manufacturing potential. Their goal is to expand this platform to refine targeting specificity, modulate the intensity of immune stimulation, and eventually translate it into human clinical applications for diseases driven by pathogenic B cells.
In recognition of its transformative potential, this research collaboration has secured over $40 million in funding from the Advanced Research Projects Agency for Health (ARPA-H), enabling continued innovation and development of next-generation cellular engineering technologies. The funding will support fine-tuning of the nanoparticles, ensuring safety, efficacy, and versatility across a range of immune-related disorders.
As these biodegradable nanoparticles advance toward clinical trials, they hold the promise to revolutionize immunotherapy by providing an off-the-shelf, highly adaptable treatment modality. This approach could significantly reduce the financial and temporal burdens associated with conventional CAR-T therapies, while expanding patient access globally. By harnessing the immune system’s intrinsic power to heal from within, this technology represents a paradigm shift toward more precise, efficient, and personalized medicine.
In summary, Johns Hopkins’ innovative nanoparticle platform has successfully demonstrated in vivo engineering of immune T cells, leading to rapid and substantial depletion of disease-associated B cells. The modularity and simplicity of the design, combined with its intracellular delivery success, mark a vital step forward in immunotherapeutic technology. As the research continues to evolve, it offers hope for safer, more accessible treatments for autoimmune diseases and hematologic cancers, redefining the landscape of future immune-based interventions.
Subject of Research: Engineering Immune T Cells In Vivo Using Biodegradable Nanoparticles for Targeted Depletion of Pathogenic B Cells in Autoimmune Diseases and Blood Cancers
Article Title: Simplified Biodegradable Nanoparticles for In Vivo Engineering of T Cells to Target Autoimmune and Hematologic Diseases
News Publication Date: March 11, 2024
Web References: https://www.science.org/doi/10.1126/sciadv.adz1722
References: DOI: 10.1126/sciadv.adz1722
Image Credits: Manav Jain and Jordan Green, Johns Hopkins Medicine
Keywords
Nanoparticles, Immunotherapy, CAR-T cells, mRNA delivery, Biodegradable polymers, T cell engineering, Autoimmune diseases, Blood cancers, In vivo gene therapy, Immune modulation, Johns Hopkins Medicine, Nanomedicine
Tags: alternative to CAR-T therapyantibody-functionalized nanoparticlesautoimmune disorder therapiesbiodegradable nanoparticles for immunotherapyblood cancer treatment innovationscost-effective cancer immunotherapyimmune cell activation nanoparticlesin vivo T cell reprogrammingJohns Hopkins Medicine researchnanoparticle-based drug deliverypolymer-based nanoparticle designtargeted immune cell elimination
